Navigation Links
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Date:9/15/2008

Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released

Concurrent with AHA Presentation

SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome (ACS) and in patients undergoing carotid endarterectomy (CEA) surgery, have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2008, taking place November 8-12 in New Orleans, LA.

Given AHA's embargo policy, the company will announce the proof of concept data from its CEA and ACS trials concurrent with the AHA sessions.

The presentation details are as follows:

Date/Time: Sunday, November 9, 2008: 5:45 p.m. CDT

Location: Ernest N. Morial Convention Center, Room 275-277

Session: Cardiovascular Seminar: Translational Trials and Strategies:

First in Man

Title: Three Months of Treatment with 5- Lipoxygenase Inhibitor VIA-2291

in Patients with Recent Acute Coronary Syndrome

Presented by: Jean-Claude Tardif, M.D., Professor and Director, Montreal

Heart Institute, Montreal, Canada

Date/Time: Sunday, November 9, 2008: 6:00 p.m. CDT

Location: Ernest N. Morial Convention Center, Room 275-277

Session: Cardiovascular Seminar: Translational Trials and Strategies:

First in Man

Title: Three Months of Treatment with 5-Lipoxygenase Inhibitor VIA- 2291

in Patients Scheduled for Elective Carotid Endarterectomy Surgery

Presented b
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Based on ... Frost & Sullivan recognises ADOCIA with the 2014 ... Leadership. By adopting a flexible business model that ... the pharmaceutical industry, ADOCIA has managed to maintain ... proteins space. "ADOCIA,s core technology is ...
(Date:9/29/2014)... , Sept. 29, 2014  On Oct. 2, ... participate in the company,s seventh Global Day of Service. ... employees will join together in a single, coordinated effort ... play. "I,m so proud of this ... talent and energy to strengthening the communities around the ...
(Date:9/29/2014)... 2014 Kush Bottles, North America,s ... and consulting services for the medical and recreational marijuana ... has assumed the role of Chief Executive Officer. ... and worked as COO until February of 2014, returned ... other ventures. His return marks a clear dedication to ...
Breaking Medicine Technology:Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 2Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 3Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 4Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 5Frost & Sullivan Confers Technology Innovation Leadership Award on ADOCIA for its Robust Pipeline of Novel Therapeutic Proteins 6Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 2Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 3Kush Bottles Co-Founder Steps into Role of CEO 2
... Target Enrollment Expected in Fourth Quarter, BERKELEY ... GNTA ) announced that the Data Safety Monitoring ... Genasense (oblimersen sodium),Injection, which is the Company,s lead ... as originally planned after initial review of,blinded safety ...
... unique Ranexa(R) mechanism of action -, CHICAGO, March ... today that ranolazine significantly (p<0.001),shortened the QT interval of ... LQT3, which is caused by a genetic mutation in ... rhythm problems, including,sudden death. Ranolazine also shortened cardiac relaxation ...
Cached Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:9/30/2014)... 2014 Visiting Nurse Association (VNA) Health ... to announce that Steven Landers, MD, MPH, president and ... “40 Under 40” award on Monday evening. The NJBIZ ... businessmen and women who have been making headlines in ... growth, professional excellence and to the community. , Dr. ...
(Date:9/30/2014)... Louis, Missouri (PRWEB) September 30, 2014 ... announce that the SLUCare Physician Group, comprised of more ... collaborating on a number of initiatives. With the ... its network size, strengthening its market footprint to better ... St. Louis area. , SLPA is a physician-led clinically ...
(Date:9/30/2014)... September 30, 2014 The global market ... USD 38.75 billion by 2020 at an estimated CAGR ... new study by Grand View Research, Inc. Increasing prevalence ... lifestyle habits such as excessive alcohol consumption and growing ... rates is expected to serve this market as a ...
(Date:9/30/2014)... 2014 Lea Blackwell, M.D., a Breast ... patients a new, more practical and comfortable option for ... mastectomies, biopsies and lumpectomy surgeries use special bras after ... seeing her patients describe the bra as scratchy, uncomfortable ... new bra in her spare time. , Ilona ...
(Date:9/30/2014)... Red Bank, NJ (PRWEB) September 30, 2014 ... largest not-for-profit visiting nurse association—is pleased to announce that ... was honored with a NJBIZ “40 Under 40” ... of New Jersey’s most accomplished young businessmen and women ... who share a commitment to business growth, professional excellence ...
Breaking Medicine News(10 mins):Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3
... ... , ... , ... ...
... The adverse affects of being overweight are not limited to ... research in the latest issue of the Journals ... (Volume 65A, Number 1). The publication presents a collection ... older persons. "One of the unanticipated consequences of ...
... exposure time , TUESDAY, Feb. 23 (HealthDay News) -- ... as much as 91 percent less radiation than standard ... generated great enthusiasm in recent years, due to its ... coronary artery disease. However, that enthusiasm has been tempered ...
... to develop dementia than non-hospitalized, study finds , TUESDAY, ... hospitalized have an increased risk of cognitive decline. , That,s ... through 2007 on 2,929 people, aged 65 and older, who ... During an average follow-up of 6.1 years, 1,287 were hospitalized ...
... ... ... ... ...
... stress hormone levels in adolescent boys and girls but ... researchers. Early treatment of depression could help reduce stress ... "This is the first time cortisol reactivity has ... obesity in girls," said Elizabeth J. Susman, the Jean ...
Cached Medicine News:Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 11Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 12Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 13Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 14Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 15Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 16Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 17Health News:Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results 18Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2Health News:New Heart CT Scans Deliver Far Less Radiation: Study 2Health News:Hospital Stays May Spur Brain Decline in Seniors 2Health News:Stopain Labels Featuring Arthritis Foundation Sponsorship Now Appearing on Retail Shelves 2Health News:Stopain Labels Featuring Arthritis Foundation Sponsorship Now Appearing on Retail Shelves 3Health News:Stopain Labels Featuring Arthritis Foundation Sponsorship Now Appearing on Retail Shelves 4Health News:Stress hormone, depression trigger obesity in girls 2
... The PowerPro® Battery System is a ... line of powered surgical instruments. The PowerPro ... software controlled battery powered instrument available on ... power system specifically designed to meet the ...
... OEC, the market leader in digital ... imaging experience and advanced technologies into ... latest entry, the MiniView 6800. This ... has the workstation components of our ...
The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes...
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Medicine Products: